Andrew Baum

Chief Strategy and Innovation Officer, Executive Vice President
Pfizer

Andrew Baum, M.D., is Pfizer's Chief Strategy and Innovation Officer, Executive Vice President, and a member of the company's Executive Leadership Team. He joined Pfizer from Citi, where he served as Head of Global Healthcare, Managing Director Equity Research. Prior to joining Citi in 2011, Dr. Baum covered European Pharmaceuticals at Morgan Stanley for fourteen years and earlier in his career was a practicing physician at the John Radcliffe Hospital, having completed his medical training at the University of Oxford.

As Pfizer's Chief Strategy and Innovation Officer, Dr. Baum is responsible for portfolio analysis and prioritization functions, business development activities, strengthening partnerships with the biotech ecosystem, and the commercial evaluation of the company’s research pipeline. Dr. Baum also chairs Pfizer's Portfolio Management Team, the company's most senior governing body responsible for portfolio management and capital deployment across its research and development pipeline, ensuring that Pfizer brings forward vaccines and medicines that have the greatest potential of addressing unmet patient needs while achieving robust reimbursement and access.

Dr. Baum holds a Master of Arts degree in Physiological Sciences and a Bachelor of Medicine, Bachelor of Surgery (BM ChB) degree from Oxford University and is a Fellow of the Royal Society of Medicine. He also has a strong background in oncology and was the first analyst to report on the transformative opportunity of cancer immunotherapy in 2011. Dr. Baum is the former co-chair of Immuno-Oncology 360° (IO360°).

In his free time, Andrew enjoys tennis, cycling, art, and spending time with his family.